Previous 10 | Next 10 |
Inmagene Biopharmaceuticals and Hutchmed (China) (HCM) said the first person, based in Australia, was dosed in a global phase 1 trial of IMG-007 to treat adult patients with moderate to severe atopic dermatitis (eczema). The early-stage trial is a ...
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, bas...
France's Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Cambridge, Mass.-based cancer drug maker Epizyme (NASDAQ:EPZM) for $247M plus contingent value right (CVR). Ipsen will begin an all-cash tender offer to acquire all outstanding shares of Epizyme (EPZM) for $1.45/share plus a CV...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00 am Eas...
TAL Education Group (NYSE:TAL) and Mercury Fintech (NASDAQ:MFH) were added to a list of companies that face possible delisting from U.S. exchanges, the Securities and Exchange Commission said on Friday. The two companies were added to the Holding Foreign Companies Accountable Act, or HF...
Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...
Cyren (CYRN) +39% on €10M sale of secure email gateway unit. Redbox Entertainment (RDBX) +25%. DBV Technologies (DBVT) +19% phase 3 trial for peanut allergy treatment in toddlers meets main goal. Brenmiller Energy (BNRG) +16%. Energy Focus (EFOI) +15%. Aldeyra Thera...
Hutchmed (China) Epizyme's (NASDAQ:EPZM) cancer drug Tazverik (tazemetostat) was approved by the Health Commission and Medical Products Administration of Hainan Province. Tazverik can now be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, under the Clinically Ur...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that TAZVERIK ® (tazemetostat) has been approved by the Health Commission and ...
The KWEB ETF has been battered significantly as investors left Chinese Internet stocks in a hurry since 2021. However, we could be in the late stage of the current malaise. Our price action analysis suggests that the worst in Chinese Internet stocks seems to have been priced in. KWEB'...
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HUTCHMED (China) Limited Website:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pati...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylig...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During t...